Psma 1 t

Manufactured by Horiba

Sourced in Germany

The PSMA-I&T is a laboratory instrument designed for the analysis and measurement of PSMA (Prostate-Specific Membrane Antigen) proteins. It provides precise and reliable data on PSMA levels, which is an important biomarker for various applications, including cancer research and diagnostics.

Automatically generated - may contain errors

Lab products found in correlation

Psma 617, by Horiba (1 mentions) Acetonitrile, by Biosolve (1 mentions) Trifluoroacetic acid, by Merck Group (1 mentions)

2 protocols using psma 1 t

Synthesis and Purification of 177Lu-labeled PSMA Peptides

Check if the same lab product or an alternative is used in the 5 most similar protocols

PSMA-I&T, PSMA-617, and the reagent and hardware kit for synthesis of ¹⁷⁷Lu peptides (SC-05) were obtained from ABX (Radeberg, Germany), acetonitrile (> 99.9%) and water (Ultrapure LC/MS) from Biosolve (Dieuze, France), octreotide (0.1 mg/ml) from Sandoz (Holzkirchen, Germany), trifluoroacetic acid from Merck (Kenilworth, United States), 96% ethanol from SAHZ (Haarlem, the Netherlands), and [¹⁷⁷Lu]LuCl₃ (EndolucinBeta) from ITM Medical Isotopes GmbH (Munich, Germany).

Aalbersberg E.A., Cao T.T., Geluk-Jonker M.M, & Hendrikx J.J. (2022). Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery. EJNMMI Radiopharmacy and Chemistry, 7, 24.

+ Open protocol

+ Expand

177Lu-PSMA-I&T Therapy Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pretherapeutic Imaging. Pretherapeutic PET imaging was performed using 18 F-PSMA-7 ( 18 F-JK-PSMA-7) or 68 Ga-PSMA ( 68 Ga-PSMA-HBED-CC). The preparations of both tracers have been described previously (13, 14) . 18 F-PSMA-7 or 68 Ga-PSMA was administered to patients on a weight-adjusted basis of 5.0 MBq/kg and 2.5 MBq/kg, respectively.
Therapy. High-purity lutetium chloride ( 177 LuCl 3 ) was obtained from ITG, and PSMA-I&T was purchased from ABX. 177 Lu-PSMA-I&T was synthesized and labeled according to a previously published protocol (15) . Patients received a mean activity of 7,209 6 379 MBq of 177 Lu-PSMA-I&T for each therapy cycle.

Hohberg M., Reifegerst M., Drzezga A., Wild M, & Schmidt M. (2023). Prediction of Response to ¹⁷⁷Lu-PSMA Therapy Based on Tumor-to-Kidney Ratio on Pretherapeutic PSMA PET/CT and Posttherapeutic Tumor-Dose Evaluation in mCRPC. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 64(11).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!